SG11201701867SA - Combination therapies with anti-cd38 antibodies - Google Patents
Combination therapies with anti-cd38 antibodiesInfo
- Publication number
- SG11201701867SA SG11201701867SA SG11201701867SA SG11201701867SA SG11201701867SA SG 11201701867S A SG11201701867S A SG 11201701867SA SG 11201701867S A SG11201701867S A SG 11201701867SA SG 11201701867S A SG11201701867S A SG 11201701867SA SG 11201701867S A SG11201701867S A SG 11201701867SA
- Authority
- SG
- Singapore
- Prior art keywords
- antibodies
- combination therapies
- therapies
- combination
- Prior art date
Links
- 238000002648 combination therapy Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462047877P | 2014-09-09 | 2014-09-09 | |
US201462087287P | 2014-12-04 | 2014-12-04 | |
PCT/US2015/048899 WO2016040294A2 (en) | 2014-09-09 | 2015-09-08 | Combination therapies with anti-cd38 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201701867SA true SG11201701867SA (en) | 2017-04-27 |
Family
ID=55436472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201701867SA SG11201701867SA (en) | 2014-09-09 | 2015-09-08 | Combination therapies with anti-cd38 antibodies |
Country Status (26)
Country | Link |
---|---|
US (2) | US20160067205A1 (en) |
EP (1) | EP3191187B1 (en) |
JP (2) | JP6707531B2 (en) |
KR (1) | KR102586588B1 (en) |
CN (1) | CN108064182B (en) |
AU (1) | AU2015315396B2 (en) |
BR (1) | BR112017004614A2 (en) |
CA (1) | CA2960494C (en) |
CL (1) | CL2017000559A1 (en) |
CR (1) | CR20170086A (en) |
EA (1) | EA035979B1 (en) |
EC (1) | ECSP17021175A (en) |
ES (1) | ES2890669T3 (en) |
GT (1) | GT201700048A (en) |
HK (1) | HK1255599A1 (en) |
IL (1) | IL251033B (en) |
MA (1) | MA40608A (en) |
MX (1) | MX2017003115A (en) |
MY (1) | MY192918A (en) |
NI (1) | NI201700027A (en) |
PE (1) | PE20170676A1 (en) |
PH (1) | PH12017500442A1 (en) |
SG (1) | SG11201701867SA (en) |
UA (1) | UA122212C2 (en) |
WO (1) | WO2016040294A2 (en) |
ZA (1) | ZA201702483B (en) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3312196B1 (en) * | 2005-03-23 | 2019-07-17 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
EP1914242A1 (en) * | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
SI2580243T1 (en) | 2010-06-09 | 2020-02-28 | Genmab A/S | Antibodies against human cd38 |
EP3620473A1 (en) | 2013-01-14 | 2020-03-11 | Xencor, Inc. | Novel heterodimeric proteins |
US11053316B2 (en) | 2013-01-14 | 2021-07-06 | Xencor, Inc. | Optimized antibody variable regions |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
ME03666B (en) | 2014-03-28 | 2020-10-20 | Xencor Inc | Bispecific antibodies that bind to cd38 and cd3 |
ES2890669T3 (en) | 2014-09-09 | 2022-01-21 | Janssen Biotech Inc | Combination therapies with anti-CD38 antibodies |
EP3223845B1 (en) | 2014-11-26 | 2021-05-19 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cd20 |
KR20170084327A (en) | 2014-11-26 | 2017-07-19 | 젠코어 인코포레이티드 | Heterodimeric antibodies that bind cd3 and cd38 |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
KR102597989B1 (en) | 2014-12-04 | 2023-11-02 | 얀센 바이오테크 인코포레이티드 | Anti-cd38 antibodies for treatment of acute myeloid leukemia |
MX2017014396A (en) | 2015-05-13 | 2018-03-23 | Morphosys Ag | Treatment for multiple myeloma (mm). |
US10766965B2 (en) | 2015-05-20 | 2020-09-08 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies |
CR20170587A (en) | 2015-06-22 | 2018-04-03 | Janssen Biotech Inc | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
WO2017079150A1 (en) | 2015-11-03 | 2017-05-11 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-cd38 antibodies and their uses |
US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
JP7058219B2 (en) | 2015-12-07 | 2022-04-21 | ゼンコア インコーポレイテッド | Heterodimer antibody that binds to CD3 and PSMA |
TWI724046B (en) * | 2016-04-06 | 2021-04-11 | 美商健生生物科技公司 | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
RU2022104399A (en) | 2016-06-14 | 2022-05-05 | Ксенкор, Инк. | BISPECIFIC ANTIBODIES-CHECKPOINT INHIBITORS |
TWI781108B (en) | 2016-07-20 | 2022-10-21 | 比利時商健生藥品公司 | Anti- gprc5d antibodies, bispecific antigen binding molecules that bind gprc5d and cd3, and uses thereof |
WO2018067946A1 (en) * | 2016-10-06 | 2018-04-12 | Syros Pharmaceuticals, Inc. | Methods of treating patients with a retinoic acid receptor-alpha agonist and an anti-cd38 antibody |
EP3434692A1 (en) * | 2017-07-24 | 2019-01-30 | Encefa | Compounds which specifically binds to cd38 for use in the treatment of neurodegenerative diseases |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to bcma and uses thereof |
AU2018359527A1 (en) | 2017-10-31 | 2020-05-07 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
WO2019094626A1 (en) * | 2017-11-08 | 2019-05-16 | Fred Hutchinson Cancer Research Center | Bispecific antibody compositions and related methods for improved pretargeted radioimunotherapies |
US20230132400A9 (en) * | 2017-11-10 | 2023-04-27 | Actinium Pharmaceuticals, Inc. | Combination therapy for treatment of a hematological disease |
JP2022521773A (en) | 2019-02-27 | 2022-04-12 | ジェネンテック, インコーポレイテッド | Dosing for treatment with anti-TIGIT antibody and anti-CD20 antibody or anti-CD38 antibody |
CN113993543A (en) | 2019-06-10 | 2022-01-28 | 武田药品工业株式会社 | Combination therapy with anti-CD 38 antibodies |
GB201916150D0 (en) * | 2019-11-06 | 2019-12-18 | Univ Of Ireland Galway | Treatment of multiple myeloma |
CA3155922A1 (en) | 2019-11-06 | 2021-05-14 | Huang Huang | Diagnostic and therapeutic methods for treatment of hematologic cancers |
US11919956B2 (en) | 2020-05-14 | 2024-03-05 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3 |
EP4200332A1 (en) | 2020-08-19 | 2023-06-28 | Xencor, Inc. | Anti-cd28 and/or anti-b7h3 compositions |
EP4225443A1 (en) | 2020-10-05 | 2023-08-16 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
CA3212665A1 (en) | 2021-03-09 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and cldn6 |
WO2022192586A1 (en) | 2021-03-10 | 2022-09-15 | Xencor, Inc. | Heterodimeric antibodies that bind cd3 and gpc3 |
TW202321308A (en) | 2021-09-30 | 2023-06-01 | 美商建南德克公司 | Methods for treatment of hematologic cancers using anti-tigit antibodies, anti-cd38 antibodies, and pd-1 axis binding antagonists |
WO2023191816A1 (en) | 2022-04-01 | 2023-10-05 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2023219613A1 (en) | 2022-05-11 | 2023-11-16 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024015897A1 (en) | 2022-07-13 | 2024-01-18 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024020432A1 (en) | 2022-07-19 | 2024-01-25 | Genentech, Inc. | Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies |
WO2024091991A1 (en) | 2022-10-25 | 2024-05-02 | Genentech, Inc. | Therapeutic and diagnostic methods for multiple myeloma |
Family Cites Families (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
WO1988001649A1 (en) | 1986-09-02 | 1988-03-10 | Genex Corporation | Single polypeptide chain binding molecules |
HUT53672A (en) | 1988-02-25 | 1990-11-28 | Gen Hospital Corp | Quick immunoselective cloning process |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
KR100206524B1 (en) | 1990-07-13 | 1999-07-01 | 어니스트 엠. 해데드 | Cd53 cell surface antigen and recombinant dna encoding the same |
US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
PT1024191E (en) | 1991-12-02 | 2008-12-22 | Medical Res Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
WO1994013804A1 (en) | 1992-12-04 | 1994-06-23 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
WO1994017184A1 (en) | 1993-01-29 | 1994-08-04 | Schering Corporation | Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto |
GB9424449D0 (en) | 1994-12-02 | 1995-01-18 | Wellcome Found | Antibodies |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
JP4233608B2 (en) | 1996-10-15 | 2009-03-04 | 塩野義製薬株式会社 | Autoantibody measurement method |
JP2001503253A (en) | 1996-10-17 | 2001-03-13 | イムノメディクス,インコーポレイテッド | Fusion proteins of non-antigenic immediate element complex and internalizing receptor system |
WO2000006194A2 (en) | 1997-02-05 | 2000-02-10 | Biotransplant, Inc. | Depletion of cells responsible for antibody-mediated graft rejection |
AU745823B2 (en) | 1997-05-02 | 2002-04-11 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Immunotoxins, comprising an onc protein, directed against malignant cells |
JP2003524587A (en) | 1998-06-05 | 2003-08-19 | マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ | Use of a genetically engineered antibody against CD38 to treat multiple myeloma |
US7223397B1 (en) * | 1999-01-07 | 2007-05-29 | Research Development Foundation | Potentiation of anti-CD38-Immunotoxin cytotoxicity |
US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
FR2807767B1 (en) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | MONOCLONAL ANTIBODIES ANTI-D |
AU6541801A (en) | 2000-06-22 | 2002-01-02 | Idec Pharma Corp | Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
EP1174440A1 (en) | 2000-07-19 | 2002-01-23 | U-BISys B.V. | A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment |
US6955884B2 (en) | 2000-10-17 | 2005-10-18 | Trudeau Institute, Inc. | Methods for identifying compounds that inhibit CD38 activity |
US20070042436A1 (en) | 2000-10-17 | 2007-02-22 | Lund Frances E | CD38 modulated chemotaxis |
US6833441B2 (en) | 2001-08-01 | 2004-12-21 | Abmaxis, Inc. | Compositions and methods for generating chimeric heteromultimers |
US20040166490A1 (en) | 2002-12-17 | 2004-08-26 | Morris David W. | Novel therapeutic targets in cancer |
ES2295639T3 (en) * | 2002-06-13 | 2008-04-16 | Crucell Holland B.V. | OX40 RECEIVER AGONISTS = (= CD134) AND THERAPEUTIC USE DESCRIPTION. |
PL2405015T3 (en) | 2003-03-05 | 2016-09-30 | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof | |
KR20170073698A (en) | 2003-05-30 | 2017-06-28 | 제넨테크, 인크. | Treatment with anti-VEGF antibodies |
US8597911B2 (en) | 2003-06-11 | 2013-12-03 | Chugai Seiyaku Kabushiki Kaisha | Process for producing antibodies |
US7902338B2 (en) | 2003-07-31 | 2011-03-08 | Immunomedics, Inc. | Anti-CD19 antibodies |
EP1689435A4 (en) | 2003-10-22 | 2007-10-03 | Univ Rochester | Anti-thymocyte antiserum and use thereof to trigger b cell apoptosis |
EP2243492A1 (en) | 2003-11-04 | 2010-10-27 | Novartis Vaccines and Diagnostics, Inc. | Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma |
ATE536376T1 (en) * | 2003-12-23 | 2011-12-15 | Crucell Holland Bv | HUMAN BINDING MOLECULE AGAINST CD1A |
NZ548990A (en) | 2004-02-06 | 2009-06-26 | Morphosys Ag | Anti-CD38 human antibodies and uses therefor |
CA2555185C (en) | 2004-02-06 | 2020-03-24 | Morphosys Ag | Anti-cd38 human antibodies and uses therefor |
EP3312196B1 (en) * | 2005-03-23 | 2019-07-17 | Genmab A/S | Antibodies against cd38 for treatment of multiple myeloma |
WO2006106905A1 (en) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
EP2799451A1 (en) | 2005-05-24 | 2014-11-05 | MorphoSys AG | Generation and profiling of fully human HuCAL GOLD®-derived therapeutic antibodies specific for human CD38 |
HUE035250T2 (en) | 2005-10-12 | 2018-05-02 | Morphosys Ag | Generation and profiling of fully human HuCAL GOLD-derived therapeutic antibodies specific for human CD38 |
MX2008007140A (en) | 2005-12-09 | 2009-03-04 | Seattle Genetics Inc | Methods of using cd40 binding agents. |
ES2395969T3 (en) | 2006-03-24 | 2013-02-18 | Merck Patent Gmbh | Genetically modified heterodimeric protein domains |
JP2009541275A (en) | 2006-06-22 | 2009-11-26 | ノボ・ノルデイスク・エー/エス | Production of bispecific antibodies |
DK2049109T3 (en) | 2006-08-02 | 2016-01-11 | Sunesis Pharmaceuticals Inc | Combined use of (+) - 1,4-dihydro-7 - [(3S, 4S) -3-methoxy-4- (methylamino) -1-pyrrolidinyl] -4-oxo-1- (2-thiazolyl) -1,8-naphthyridine-3-carboxylic acid and cytarabine (Ara-C) for the treatment of leukemia |
WO2008073160A2 (en) | 2006-08-17 | 2008-06-19 | The Trustees Of Columbia University In The City Of New York | Methods for converting or inducing protective immunity |
TR201910145T4 (en) * | 2006-09-26 | 2019-08-21 | Genmab As | Anti-CD38 plus corticosteroids plus a corticosteroid non-chemotherapeutic for treating tumors. |
EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
US7618992B2 (en) | 2006-12-29 | 2009-11-17 | Astellas Pharma Inc. | Method of treating cancer by co-administration of anticancer agents |
ES2593484T3 (en) | 2007-03-29 | 2016-12-09 | Genmab A/S | Bispecific antibodies and their production methods |
CA2688563A1 (en) | 2007-06-01 | 2008-12-11 | Biogen Idec Ma Inc. | Cripto binding molecules |
US20090076249A1 (en) * | 2007-09-19 | 2009-03-19 | Michel De Weers | Antibodies against CD38 for treatment of multiple myeloma |
US8748356B2 (en) | 2007-10-19 | 2014-06-10 | Janssen Biotech, Inc. | Methods for use in human-adapting monoclonal antibodies |
AU2008323815B2 (en) | 2007-11-09 | 2013-09-19 | Novartis Ag | Uses of anti-CD40 antibodies |
EP2237798A2 (en) | 2007-12-12 | 2010-10-13 | Imperial Innovations Limited | Methods |
JP2011507519A (en) | 2007-12-19 | 2011-03-10 | セントコア・オーソ・バイオテツク・インコーポレーテツド | Design and generation of human de novo pIX phage display library via fusion to pIX or pVII, vectors, antibodies, and methods |
PT2235064E (en) | 2008-01-07 | 2016-03-01 | Amgen Inc | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
WO2009111508A2 (en) | 2008-03-03 | 2009-09-11 | Dyax Corp. | Metalloproteinase 9 and metalloproteinase 2 binding proteins |
AR072947A1 (en) | 2008-03-25 | 2010-10-06 | Glycart Biotechnology Ag | COMBINATION THERAPY OF AN ANTI-CD20 TYPE II ANTIBODY WITH CYTOTOXICITY, INCREASED ANTIBODY DEPENDENT CELL (CCDA), PHARMACEUTICAL COMPOSITION, ANTI-CD20 TYPE II ANTIBODY |
KR20160052812A (en) | 2008-04-14 | 2016-05-12 | 할로자임, 아이엔씨 | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions |
US9029508B2 (en) | 2008-04-29 | 2015-05-12 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
BRPI0921482B1 (en) | 2008-11-07 | 2022-09-20 | Amgen Research (Munich) Gmbh | USE OF A CD19XCD3 SINGLE CHAIN ANTIBODY CONSTRUCTION IN THE TREATMENT OF ACUTE LYMPHOBLASTIC LEUKEMIA |
EP2191843A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide |
EP2191842A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and cytarabine |
EP2191841A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine |
EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
WO2010129304A2 (en) | 2009-04-27 | 2010-11-11 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
US8865710B2 (en) | 2009-05-14 | 2014-10-21 | Ambit Biosciences Corporation | Methods of treating proliferative diseases |
DK2477603T3 (en) | 2009-09-17 | 2016-06-13 | Baxalta Inc | STABLE CO-DEVELOPMENT OF hyaluronidase and Immunoglobulin, AND METHODS OF USE THEREOF |
ES2672121T3 (en) | 2009-10-07 | 2018-06-12 | Macrogenics, Inc. | Polypeptides containing Fc region that have an enhanced effector function due to alterations in the degree of fucosylation, and methods for their use |
EP2327725A1 (en) | 2009-11-26 | 2011-06-01 | InflaRx GmbH | Anti-C5a binding moieties with high blocking activity |
GB201003701D0 (en) | 2010-03-05 | 2010-04-21 | Cilian Ag | System for the expression of a protein |
US20130137134A1 (en) | 2010-03-29 | 2013-05-30 | Ben Gurion University Of The Negev Research And Development Authority | Method and system for detecting and monitoring hematological cancer |
US9150663B2 (en) | 2010-04-20 | 2015-10-06 | Genmab A/S | Heterodimeric antibody Fc-containing proteins and methods for production thereof |
JP6022444B2 (en) | 2010-05-14 | 2016-11-09 | ライナット ニューロサイエンス コーポレイション | Heterodimeric protein and method for producing and purifying it |
SI2580243T1 (en) * | 2010-06-09 | 2020-02-28 | Genmab A/S | Antibodies against human cd38 |
EP2420253A1 (en) | 2010-08-20 | 2012-02-22 | Leadartis, S.L. | Engineering multifunctional and multivalent molecules with collagen XV trimerization domain |
HUE031956T2 (en) * | 2010-09-27 | 2017-08-28 | Morphosys Ag | Anti-cd38 antibody and lenalidomide or bortezomib for the treatment of multiple myeloma and nhl |
JP6167040B2 (en) | 2010-11-05 | 2017-07-19 | ザイムワークス,インコーポレイテッド | Design of stable heterodimeric antibodies with mutations in the Fc domain |
US9358233B2 (en) | 2010-11-29 | 2016-06-07 | Boehringer Ingelheim International Gmbh | Method for treating acute myeloid leukemia |
UA112170C2 (en) | 2010-12-10 | 2016-08-10 | Санофі | ANTI-TUMOR COMBINATION CONTAINING AN ANTIBODY SPECIFICALLY RECOGNIZING CD38 AND BORTESOMB |
JOP20210044A1 (en) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | Anti-cd38 antibodies |
CL2013001944A1 (en) | 2010-12-30 | 2014-09-12 | Takeda Pharmaceutical | Isolated antibody that specifically binds to human cd38 and cinomolgo cd38; nucleic acid encoding it; host cell; Method of production; and its use to treat an autoimmune disease. |
PT2688887E (en) | 2011-03-23 | 2015-07-06 | Amgen Inc | Fused tricyclic dual inhibitors of cdk 4/6 and flt3 |
EP2561868A1 (en) | 2011-08-24 | 2013-02-27 | Anton Bernhard Van Oosten | Pharmaceutical compositions comprising hydroxychloroquine (HCQ), Curcumin, Piperine/BioPerine and uses thereof in the medical field |
CN109022465B (en) | 2011-10-28 | 2022-04-29 | 特瓦制药澳大利亚私人有限公司 | Polypeptide constructs and uses thereof |
JP6448533B2 (en) | 2012-05-15 | 2019-01-09 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | Cancer immunotherapy by disrupting PD-1 / PD-L1 signaling |
US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
MX368288B (en) * | 2012-09-25 | 2019-09-27 | Morphosys Ag | Combinations and uses thereof. |
WO2014068114A1 (en) | 2012-11-05 | 2014-05-08 | Morphosys Ag | Radiolabelled antibody and uses thereof |
WO2014142220A1 (en) | 2013-03-13 | 2014-09-18 | アステラス製薬株式会社 | Anti-tumor agent |
US20140271644A1 (en) | 2013-03-15 | 2014-09-18 | Memorial Sloan-Kettering Cancer Center | Combination/adjuvant therapy for wt-1-positive disease |
ES2774976T3 (en) | 2013-04-29 | 2020-07-23 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions with attenuated interferon alfa-2b |
US20140356318A1 (en) | 2013-05-28 | 2014-12-04 | Israel Barken | Adoptive cell therapy with specific regulatory lymphocytes |
AU2014290186A1 (en) | 2013-07-15 | 2016-02-04 | The Board Of Trustees Of The Leland Stanford Junior University | Medical uses of CD38 agonists |
US20150118251A1 (en) | 2013-10-31 | 2015-04-30 | Sanofi | Specific anti-cd38 antibodies for treating human cancers |
WO2015067570A2 (en) | 2013-11-06 | 2015-05-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical combinations comprising cd33 antibodies and de-methylating agents |
US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
EP3154581B1 (en) | 2014-06-16 | 2019-02-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Blocking cd38 using anti-cd38 f(ab')2 to protect nk cells |
WO2015195555A1 (en) | 2014-06-16 | 2015-12-23 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Blocking cd38 using anti-cd38 antibody conjugated to protein g to protect nk cells |
US9499514B2 (en) | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
ES2890669T3 (en) | 2014-09-09 | 2022-01-21 | Janssen Biotech Inc | Combination therapies with anti-CD38 antibodies |
KR102597989B1 (en) | 2014-12-04 | 2023-11-02 | 얀센 바이오테크 인코포레이티드 | Anti-cd38 antibodies for treatment of acute myeloid leukemia |
US10766965B2 (en) | 2015-05-20 | 2020-09-08 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of light chain amyloidosis and other CD38-positive hematological malignancies |
CR20170587A (en) | 2015-06-22 | 2018-04-03 | Janssen Biotech Inc | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
BR112017027990A2 (en) | 2015-06-24 | 2018-08-28 | Janssen Biotech, Inc. | immune modulation and treatment of solid tumors with antibodies that specifically bind to cd38 |
US20170121417A1 (en) | 2015-11-03 | 2017-05-04 | Janssen Biotech, Inc. | Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses |
WO2017079150A1 (en) | 2015-11-03 | 2017-05-11 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-cd38 antibodies and their uses |
JP2019527678A (en) | 2016-06-28 | 2019-10-03 | ユーエムセー・ユトレヒト・ホールディング・ベー・フェー | Treatment of IgE-mediated diseases with antibodies that specifically bind to CD38 |
US20180117150A1 (en) | 2016-11-01 | 2018-05-03 | Janssen Biotech, Inc. | Combination Therapies for CD38-Positive Hematological Malignances with ANTI-CD38 Antibodies and Cyclophosphamide |
AU2018359527A1 (en) | 2017-10-31 | 2020-05-07 | Janssen Biotech, Inc. | Methods of treating high risk multiple myeloma |
-
2015
- 2015-09-08 ES ES15839752T patent/ES2890669T3/en active Active
- 2015-09-08 US US14/847,428 patent/US20160067205A1/en not_active Abandoned
- 2015-09-08 MA MA040608A patent/MA40608A/en unknown
- 2015-09-08 BR BR112017004614-8A patent/BR112017004614A2/en not_active Application Discontinuation
- 2015-09-08 WO PCT/US2015/048899 patent/WO2016040294A2/en active Application Filing
- 2015-09-08 CA CA2960494A patent/CA2960494C/en active Active
- 2015-09-08 MY MYPI2017700796A patent/MY192918A/en unknown
- 2015-09-08 CR CR20170086A patent/CR20170086A/en unknown
- 2015-09-08 CN CN201580060898.4A patent/CN108064182B/en active Active
- 2015-09-08 PE PE2017000431A patent/PE20170676A1/en unknown
- 2015-09-08 UA UAA201703276A patent/UA122212C2/en unknown
- 2015-09-08 EA EA201790548A patent/EA035979B1/en unknown
- 2015-09-08 JP JP2017513177A patent/JP6707531B2/en active Active
- 2015-09-08 MX MX2017003115A patent/MX2017003115A/en unknown
- 2015-09-08 AU AU2015315396A patent/AU2015315396B2/en active Active
- 2015-09-08 SG SG11201701867SA patent/SG11201701867SA/en unknown
- 2015-09-08 KR KR1020177009199A patent/KR102586588B1/en active IP Right Grant
- 2015-09-08 EP EP15839752.1A patent/EP3191187B1/en active Active
-
2016
- 2016-12-21 US US15/386,391 patent/US10604580B2/en active Active
-
2017
- 2017-03-08 CL CL2017000559A patent/CL2017000559A1/en unknown
- 2017-03-08 NI NI201700027A patent/NI201700027A/en unknown
- 2017-03-08 IL IL251033A patent/IL251033B/en unknown
- 2017-03-09 GT GT201700048A patent/GT201700048A/en unknown
- 2017-03-09 PH PH12017500442A patent/PH12017500442A1/en unknown
- 2017-04-06 EC ECIEPI201721175A patent/ECSP17021175A/en unknown
- 2017-04-07 ZA ZA2017/02483A patent/ZA201702483B/en unknown
-
2018
- 2018-11-19 HK HK18114728.0A patent/HK1255599A1/en unknown
-
2020
- 2020-05-18 JP JP2020086765A patent/JP2020143108A/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1255599A1 (en) | Combination therapies with anti-cd38 antibodies | |
ZA201708541B (en) | Combination therapies with anti-cd38 antibodies | |
IL250512B (en) | Combination therapies with anti cd40 antibodies | |
IL252442A0 (en) | Combination therapies | |
IL250583A0 (en) | Anti-tigit antibodies | |
SG11201703403TA (en) | Anti-tim-3 antibodies | |
SG11201703346PA (en) | Anti-tim-3 antibodies | |
IL252422A0 (en) | Effector-deficient anti-cd32a antibodies | |
IL250374A0 (en) | Anti-ceramide antibodies | |
IL247988A0 (en) | Antibodies against hpa-1a | |
EP3129022A4 (en) | Combination therapies with curaxins | |
GB201419089D0 (en) | Anti-TIM-3 antibodies | |
GB201419092D0 (en) | Anti-TIM-3 antibodies | |
GB201417614D0 (en) | Antibodies | |
GB201414270D0 (en) | Antibodies | |
GB201405775D0 (en) | Antibodies | |
GB201401200D0 (en) | Antibodies |